Press Release Archive
-
Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy
-
Johnson & Johnson Announces Acceptance Of Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics
-
Janssen Expands the EXPLORER Global Cardiovascular Research Program with Three New Studies Evaluating XARELTO® in Patients at Risk for Venous Thromboembolism
-
Johnson & Johnson Enters Agreement to be Official Healthcare Partner of the USOJohnson & Johnson announced it has entered a multi-year agreement to be the Official Healthcare Partner of the USO. The announcement was made today during a ceremony to mark the opening of the USO’s ...
-
Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy In Treatment Of Moderate To Severe Plaque PsoriasisResults from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab
-
Siltuximab Receives CHMP Positive Opinion for use in the Treatment of Multicentric Castleman’s Disease, a very Rare Blood Disorder
-
Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays RelapseIndependent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy
-
New Depuy Synthes Advantage™ Provides Solutions Focused On Improving Clinical And Economic Outcomes And Patient SatisfactionSolutions include MedTrak, Inc.’s CareSense System To Track and Analyze Patient Outcomes, Patient Satisfaction and Cost
-
Depuy Synthes Joint Reconstruction Introduces Two New Knee Technologies For The ATTUNE® Knee System
-
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results